Abstract
Epidemiological studies suggest a strong association between hypertension and ischemic heart disease (IHD), and hypertension is a major independent risk factor for the development of cardiovascular disease (CVD) including myocardial infarction (MI) and stroke. The primary objective of the management of hypertension in patients with IHD is modification of the balance between myocardial oxygen supply and demand to improve symptoms and reduce future cardiovascular adverse events. Patients with hypertension and heart failure constitute another important cohort in this high risk group. While several classes of antihypertensive agents have been shown to be beneficial in treating these patients, there are also several classes of drugs that should be avoided when treating hypertension in patients with IHD and heart failure. This review discusses which antihypertensive drugs should be used in patients who have established IHD with angina pectoris, in those with acute coronary syndromes and MI, and in those with heart failure. These recommendations are based on current guidelines. Finally, although there may be some differences in cardiovascular risk reduction among antihypertensive agents, the most important objective in hypertension management is to adequately control blood pressure irrespective of the agent used.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Optimal Management of Hypertension in patients with Ischemic Heart Disease
Volume: 7 Issue: 3
Author(s): Debabrata Mukherjee and Charles L. Campbell
Affiliation:
Abstract: Epidemiological studies suggest a strong association between hypertension and ischemic heart disease (IHD), and hypertension is a major independent risk factor for the development of cardiovascular disease (CVD) including myocardial infarction (MI) and stroke. The primary objective of the management of hypertension in patients with IHD is modification of the balance between myocardial oxygen supply and demand to improve symptoms and reduce future cardiovascular adverse events. Patients with hypertension and heart failure constitute another important cohort in this high risk group. While several classes of antihypertensive agents have been shown to be beneficial in treating these patients, there are also several classes of drugs that should be avoided when treating hypertension in patients with IHD and heart failure. This review discusses which antihypertensive drugs should be used in patients who have established IHD with angina pectoris, in those with acute coronary syndromes and MI, and in those with heart failure. These recommendations are based on current guidelines. Finally, although there may be some differences in cardiovascular risk reduction among antihypertensive agents, the most important objective in hypertension management is to adequately control blood pressure irrespective of the agent used.
Export Options
About this article
Cite this article as:
Mukherjee Debabrata and Campbell L. Charles, Optimal Management of Hypertension in patients with Ischemic Heart Disease, Cardiovascular & Hematological Agents in Medicinal Chemistry 2009; 7 (3) . https://dx.doi.org/10.2174/187152509789105435
DOI https://dx.doi.org/10.2174/187152509789105435 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Investigation on Risk Factor of Vascular Thrombotic Diseases in Patients with Obstructive Sleep Apnea Hypopnea Syndrome
Vascular Disease Prevention (Discontinued) Use of BNP and CRP as Biomarkers in Assessing Cardiovascular Disease:Diagnosis Versus Risk
Current Vascular Pharmacology Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism A Novel Potential Reproductive Effects of Pterocarpus marsupium Methanolic Extract on Testosterone Propionate Induced Polycystic Ovary Syndrome in Female Albino Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design Mannose Binding Lectin: A Potential Biomarker for Many Human Diseases
Current Medicinal Chemistry Obesity, Diabetes and Cardiovascular Diseases in India: Public Health Challenges
Current Diabetes Reviews Chagas Heart Disease Pathogenesis: One Mechanism or Many?
Current Molecular Medicine Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications
Current Medicinal Chemistry Toll-like Receptors and Diabetes Complications: Recent Advances
Current Diabetes Reviews The Impact of Diabetes on Mortality Among Elderly Patients Admitted for Treatment at a Hospital for Cardiovascular Disease in Southern Brazil
Current Diabetes Reviews Targeting Adenosine Signaling to Treatment of Diabetic Nephropathy
Current Drug Targets Nutriproteomics and Nutrigenomics: Exploring the Mechanism Behind omega-3 Polyunsaturated Fatty Acids, Homocysteine and Glucose Metabolism
Current Proteomics Novel Findings and Therapeutic Targets on Cardioprotection of Ischemia/ Reperfusion Injury in STEMI
Current Pharmaceutical Design Molecular Determinants of the Cardiometabolic Phenotype
Endocrine, Metabolic & Immune Disorders - Drug Targets Heart Failure in South America
Current Cardiology Reviews Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal Persistence of Trypanosoma cruzi in Experimental Chagasic Cardiomyopathy
Anti-Infective Agents